PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiAll Plans · Prior Auth · Medical Policy · Allergy & Immunology, PharmacyHigh impact

Hereditary Angioedema (HAE)

Effective date
Apr 1, 2026
Identified
Jun 20, 2026

Summary

Effective 04/01/2026, the BCBSMS hereditary angioedema policy added Andembry (garadacimab-gxii), Dawnzera (donidalorsen), and Ekterly (sebetralstat) to its list of drugs, and Sajazir (icatibant) was added effective the same date. The revised criteria cover documentation of recurrent angioedema episodes and HAE subtype, and add separate criteria for acute attack treatment and for routine prophylaxis. Dawnzera and Ekterly are considered not medically necessary because other formulary alternatives are covered by the Plan for both acute and prophylactic treatment of HAE attacks.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 8 steps
01Already effective 04/01/2026: Billing team, perform a formulary drug search on the patient's member ID to confirm the drug is covered under their benefit plan.
02Prior authorization is required under this policy.
03Documentation must show one of the listed HAE criteria, such as C1-INH protein level, C1-INH function level, and C4 level measurements, a mutation in the C1-INH gene, or, for HAE-unknown, confirmation by an HAE specialist with medical records.
04Medications known to cause angioedema, such as ACE inhibitors, estrogens, angiotensin II receptor blockers, and NSAIDs, must have been evaluated and discontinued when appropriate.
05The prescriber must be a specialist or have consulted one, such as an allergist or immunologist.
06Samples used by the individual are not considered current or stable therapy.
07Andembry is limited to 200mg once monthly, and the initial approval length is 12 months.
08Services for delivery or administration of a medication that were not approved through the BCBSMS PA review are considered not medically necessary.

Codes mentioned

J0597J0599J1744J0593J0596J0598J1290D84.1

Original notice

Hereditary Angioedema (HAE)
bcbsms.com · Always check the source before changing claims.
View original ↗

Related policy hubs

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account